Literature DB >> 25383821

Bilateral nanophthalmic uveal effusion syndrome: clinical presentation and surgical management.

Robin G Abell1, Nathan M Kerr, Brendan J Vote.   

Abstract

PURPOSE: To describe the clinical presentation and surgical management of bilateral uveal effusion syndrome in a type 1 diabetic patient with nanophthalmos.
METHODS: A 38-year-old man presented with decreased visual acuity. Fundus examination revealed exudative retinal detachment and choroidal folding. Ultrasound examination confirmed thickened sclera, choroidal effusion, and nanophthalmos. Partial thickness scleral windows and subscleral sclerectomy were performed. The patient returned 2 years postoperatively with the same presentation in the contralateral eye.
RESULTS: After subscleral sclerectomy, intraocular pressure remained stable and the patient recovered premorbid vision in both eyes. At 4 years of follow-up, the patient's vision had remained stable without the need for further treatment.
CONCLUSION: The association of uveal effusion syndrome with diabetes and other autoimmune disorders is unclear, warranting further research. Uveal effusion syndrome can be managed effectively by partial thickness scleral windows and sclerectomy with improvement and maintenance of visual acuity.

Entities:  

Year:  2013        PMID: 25383821     DOI: 10.1097/ICB.0b013e318297f6c1

Source DB:  PubMed          Journal:  Retin Cases Brief Rep        ISSN: 1935-1089


  3 in total

1.  Bilateral uveal effusions in a 23-year-old man.

Authors:  Karen W Jeng-Miller; Eric D Gaier; Angela V Turalba
Journal:  Digit J Ophthalmol       Date:  2018-05-22

2.  Unusual rapid resolution of postsclerectomy exudative retinal detachment with topical NSAIDs therapy in a case of nanophthalmos.

Authors:  Boding Tong; Chao Wang; Xin Qi
Journal:  J Int Med Res       Date:  2019-05-13       Impact factor: 1.671

3.  Outcomes of Baerveldt Glaucoma Drainage Devices in Pediatric Eyes.

Authors:  Adam Jacobson; Cagri G Besirli; Brenda L Bohnsack
Journal:  J Glaucoma       Date:  2021-12-21       Impact factor: 2.290

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.